色婷婷综合成人av_99久久精品国产毛片_成人一区二区在线_国产91丝袜在线播放_久久人人爽人人爽人人片av免费_欧美伊人

美國ChemoCentryx
ChemoCentryx公司正在開發用于治療自身免疫性疾病、炎性疾病和腫瘤的口服藥物，這些藥物主要針對趨化因子和化學誘導系統。
ChemoCentryx公司最領先的藥物是Traficet-EN，目前處于治療克羅恩病的Ⅲ期臨床試驗階段和乳糜瀉的Ⅱ期臨床階段以及潰瘍性結腸炎的I期臨床研究階段。另外，該公司還有一些藥物處于I期臨床階段，分別是治療胃腸道疾病的CCX025、治療脈管狹窄和多發性硬化癥的CCX140以及治療類風濕性關節炎的CCX354。



ChemoCentryx, Inc. (NASDAQ: CCXI) is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics that target the chemokine and chemoattractant systems in order to treat autoimmune diseases, inflammatory disorders and cancer. The chemokine system is a biological network that regulates inflammation via a collection of secreted chemokine molecules, or ligands, and their specific cell surface receptors. Based on its proprietary drug discovery and drug development platform, ChemoCentryx has generated multiple clinical and preclinical-stage programs, each targeting distinct chemokine and chemoattractant receptors with different small molecule compounds.